Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes

Cited by (667)

Items 101–200 of 667

1. Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association
   Robert A. Gabbay, Debbie Kendall, Christine Beebe, John K. Cuddeback, Todd M. Hobbs, Naeem D. Khan, Sandra Leal, Eden M Miller, Lucia M. Novak, Swapnil N. Rajpathak et al. · 2020 · Clinical Diabetes
2. Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
   Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D., for the VADT Investigators · 2017 · Diabetes Care
3. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
   David E. Kloecker, Melanie Jane Davies, Kamlesh Khunti, Francesco Zaccardi · 2020 · Annals of Internal Medicine
4. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
   Marian Sue Kirkman, Hussain Mahmud, Mary T. Korytkowski · 2018 · Endocrinology and Metabolism Clinics of North America
5. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory
   Sho‐ichi Yamagishi, Nobutaka Nakamura, Takanori Matsui · 2016 · Journal of Diabetes
6. IgE Contributes to Atherosclerosis and Obesity by Affecting Macrophage Polarization, Macrophage Protein Network, and Foam Cell Formation
   Xian Zhang, Jie Li, Songyuan Luo, Minjie Wang, Qin Miao Huang, Zhiyong Deng, Caroline de Febbo, Aida Daoui, Pei Xiong Liew, Galina K. Sukhova et al. · 2020 · Arteriosclerosis Thrombosis and Vascular Biology
7. Understanding Metabolic Memory: A Tale of Two Studies
   Rachel G. Miller, Trevor John Orchard · 2020 · Diabetes
8. Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
   Viswanathan Mohan, Kamlesh Khunti, Siew Pheng Chan, Fadlo Fraige Filho, Nam Quang Tran, Kaushik L. Ramaiya, Shashank Joshi, Ambrish Mithal, Maïmouna Ndour Mbaye, Nemencio Almare Nicodemus et al. · 2019 · Diabetes Therapy
9. Epigenetics in diabetic nephropathy, immunity and metabolism
   Keating, Samuel T., van Diepen, Janna A., Riksen, Niels P., El-Osta, Assam · 2018 · Diabetologia
10. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes
    Stahel, Priska, Xiao, Changting, Hegele, Robert A., Lewis, Gary F. · 2018 · Canadian Journal of Cardiology
11. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
    Kimberly N. Hong, Valentín Fuster, Robert S. Rosenson, Clive Rosendorff, Deepak L. Bhatt · 2017 · Journal of the American College of Cardiology
12. The trials and tribulations of determining HbA1c targets for diabetes mellitus
    Klara Rachel Klein, John B. Buse · 2020 · Nature Reviews Endocrinology
13. An update on DPP-4 inhibitors in the management of type 2 diabetes
    Avivit Cahn, Simona Cernea, Itamar Raz · 2016 · Expert Opinion on Emerging Drugs
14. Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population-based cohort study of 24,752 metformin initiators
    Svensson, Elisabeth, Baggesen, Lisbeth M., Johnsen, Søren P., Pedersen, Lars, Nørrelund, Helene, Buhl, Esben S., Haase, Christiane L., Thomsen, Reimar W. · 2017 · Diabetes Care
15. Advances in the management of type 2 diabetes in adults
    Rodolfo Javier Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, Rozalina G. McCoy · 2023 · BMJ Medicine
16. The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools
    Kuo‐Li Pan, Yung‐Chien Hsu, Shih‐Tai Chang, Chang‐Min Chung, Chun‐Liang Lin · 2023 · International Journal of Molecular Sciences
17. Association between fasting glucose and all-cause mortality according to sex and age: a prospective cohort study
    Sang‐Wook Yi, Sangkyu Park, Yong‐ho Lee, Hyang-Jeong Park, Beverley Balkau, Jee‐Jeon Yi · 2017 · Scientific Reports
18. Association Between Triglyceride Level and Glycemic Control Among Insulin-Treated Patients With Type 2 Diabetes
    Deqiang Zheng, Jingtao Dou, Guangxu Liu, Yuesong Pan, Yuxiang Yan, Fen Liu, Herbert Y. Gaisano, Juming Lu, Yan Ling He · 2018 · The Journal of Clinical Endocrinology & Metabolism
19. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
    Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim et al. · 2024 · Diabetes & Metabolism Journal
20. Management of diabetes mellitus in older people with comorbidities
    Elbert S. Huang · 2016 · BMJ
21. HbA1c method performance: The great success story of global standardization
    Emma English, Erna Lenters‐Westra · 2018 · Critical Reviews in Clinical Laboratory Sciences
22. Renal physiology of glucose handling and therapeutic implications
    David Z.I. Cherney, Mehmet Kanbay, Julie A. Lovshin · 2019 · Nephrology Dialysis Transplantation
23. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes
    Abdelhafiz, A.H., Sinclair, A.J. · 2018 · Journal of Diabetes and its Complications
24. Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications
    Ted D. Adams, David E Arterburn, David M. Nathan, Robert H. Eckel · 2016 · Diabetes Care
25. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios
    Francesco Prattichizzo, Paola de Candia, Valeria De Nigris, Antonio Nicolucci, Antonio Ceriello · 2020 · Metabolism
26. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention
    Sho‐ichi Yamagishi · 2019 · Circulation Journal
27. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
    Keith C. Ferdinand, Fady T. Botros, Charles Messan Atisso, Philip T. Sager · 2016 · Cardiovascular Diabetology
28. Effectiveness of the chronic care model for adults with type 2 diabetes in primary care: a systematic review and meta-analysis
    Lay Hoon Goh, Chiew Jiat Rosalind Siah, Wilson Tam, E Shyong Tai, Doris Yee Ling Young · 2022 · Systematic Reviews
29. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
    Eberhard Standl, Oliver Schnell, Darren K. McGuire · 2016 · Circulation Research
30. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
    Bart Staels · 2017 · The American Journal of Cardiology
31. Diabetes‐mediated myelopoiesis and the relationship to cardiovascular risk
    Tessa J. Barrett, Andrew James Murphy, Ira J. Goldberg, Edward A A Fisher · 2017 · Annals of the New York Academy of Sciences
32. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial
    S. C. J. van Steen, Ilse C. Schrieks, Joost B.L. Hoekstra, Abraham Michael Lincoff, Jean‐Claude Tardif, Linda Mellbin, Lars Rydén, Diederick E. Grobbee, J. Hans DeVries, on behalf of the AleCardio study group · 2017 · European Journal of Preventive Cardiology
33. d-Ribose contributes to the glycation of serum protein
    Yao Chen, Lexiang Yu, Yujing Wang, Wei Yan, Yong Xu, Tao He, Rongqiao He · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
34. Increased Cardiovascular Disease Risk in Veterans With Mental Illness
    Mary C. Vance, Wyndy L. Wiitala, Jeremy B. Sussman, Paul Pfeiffer, Rodney A. Hayward · 2019 · Circulation Cardiovascular Quality and Outcomes
35. Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the “Gordian Knot”?
    Louis Monnier, C Colette, David R. Owens · 2021 · Diabetes & Metabolism
36. My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy
    Manoja Kumar Brahma, Mark E. Pepin, Adam R. Wende · 2017 · Diabetes & Metabolism Journal
37. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation
    Dandan Wang, Xiaoyue Hu, Seung Hee Lee, Feng Chen, Kai Jiang, Zizhuo Tu, Zejian Liu, Jing Du, Li Wang, Chaoying Yin et al. · 2018 · JACC Basic to Translational Science
38. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
    Dimitrios Patoulias, Christodoulos E. Papadopoulos, Konstantinos Stavropoulos, Ioanna Zografou, Michael N. Doumas, Asterios I. Karagiannis · 2020 · Journal of Clinical Hypertension
39. Diabetic dyslipidaemia
    Soran, Handrean, Schofield, Jonathan D., Adam, Safwaan, Durrington, Paul N. · 2016 · Current Opinion in Lipidology
40. Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes.
    Greene, Stephen J., Vaduganathan, Muthiah, Khan, Muhammad Shahzeb, Bakris, George L., Weir, Matthew R., Seltzer, Jonathan H., Sattar, Naveed, McGuire, Darren K., Januzzi, James L., Stockbridge, Norman et al. · 2018 · Journal of the American College of Cardiology
41. Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study
    Junyu Pei, Xiaopu Wang, Zeyu Pei, Xinqun Hu · 2023 · Cardiovascular Diabetology
42. Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
    Jingyang Chen, Dong Yin, Kefei Dou · 2023 · Cardiovascular Diabetology
43. A1C targets should be personalized to maximize benefits while limiting risks
    Riddle, Matthew C., Gerstein, Hertzel C., Holman, Rury R., Inzucchi, Silvio E., Zinman, Bernard, Zoungas, Sophia, Cefalu, William T. · 2018 · Diabetes Care
44. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
    Francesco Giorgino, Philip Home, Jaakko O. Tuomilehto · 2016 · Diabetes Care
45. Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes
    Chia-Lin Lee, Wayne Huey‐Herng Sheu, I‐Te Lee, Shih‐Yi Lin, Wen‐Miin Liang, Jun‐Sing Wang, Yufen Li · 2017 · Diabetes & Metabolism
46. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
    Kevin O’Fee, Elena Deych, Oriana Ciani, David Brown · 2021 · JAMA Internal Medicine
47. Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
    Jin Kyung Hwang, Seung Hwa Lee, Young Bin Song, Joonghyun Ahn, Keumhee Chough Carriere, Mi Ja Jang, Taek Kyu Park, Seung‐Hyuk Choi, Jeong Hoon Yang, Jin‐Ho Choi et al. · 2017 · Circulation Cardiovascular Interventions
48. Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes
    Jordi Merino, Aaron Leong, Daniel C. Posner, Bianca Porneala, L. Masana, Josée Dupuis, José C. Florez · 2017 · Diabetes Care
49. An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment
    Makam, Anil N., Nguyen, Oanh K. · 2017 · Circulation
50. Diabetes Mellitus in Peru
    Jaime E. Villena · 2015 · Annals of Global Health
51. Diabetes-Related Cardiac Dysfunction
    Lamario J. Williams, Brenna G. Nye, Adam R. Wende · 2017 · Endocrinology and Metabolism
52. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura, Baroni, Marco Giorgio · 2020 · Advances in Experimental Medicine and Biology
53. Association between unfavorable lipid profile and glycemic control in patients with type 2 diabetes mellitus
    Aleksandra N. Klisic, Nebojša Kavarić, Milovan Jovanović, Elvir Zvrko, Verica Skerovic, Andjelka Scepanovic, Darko Medin, Ana Ninić · 2017 · Journal of Research in Medical Sciences
54. Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology
    Paul Elie Valensi, Patrick Henry, Franck Boccara, Emmanuel Cosson, Gaëtan Prévost, Joseph Emmerich, Laura Ernande, Dany Michel Marcadet, Élie Mousseaux, François Rouzet et al. · 2020 · Diabetes & Metabolism
55. JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
    Akira Fujiyoshi, Shun Kohsaka, Jun Hata, Mitsuhiko Hara, Hisashi Kai, Daisaku Masuda, Naomi Miyamatsu, Yoshihiko Nishio, Masatsune Ogura, Masataka Sata et al. · 2024 · Circulation Journal
56. Current Antidiabetic Drugs
    Hossain, Md. Akil, Pervin, Rokeya · 2018 · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
57. Diabetes: An Update on the Pandemic and Potential Solutions
    Mohammed Kumail Ali, Karen R. Siegel, Eeshwar K Chandrasekar, Nikhil Tandon, Pablo Aschner Montoya, Jean Claude Mbanya, Juliana C.N. Chan, Ping Zhang, K.M. Venkat Narayan · 2017 · World Bank, Washington, DC eBooks
58. Hypoglycaemia and cardiac arrhythmias in diabetes
    Andreas Andersen, Peter Godsk Jørgensen, Filip Krag Knop, Tina Vilsbøll · 2020 · Therapeutic Advances in Endocrinology and Metabolism
59. The legacy effect in diabetes: are there long-term benefits?
    Rachel Folz, Neda Laiteerapong · 2021 · Diabetologia
60. Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials
    Soo Kyung Lim, Tae Jung Oh, Jesse Dawson, Naveed A. Sattar · 2019 · Diabetes Obesity and Metabolism
61. MicroRNAs and Circular RNAs in Lipoprotein Metabolism
    Pablo Fernández‐Tussy, Inmaculada Ruz‐Maldonado, Carlos F Fernandez-Hernando · 2021 · Current Atherosclerosis Reports
62. A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT)
    Aramesh Saremi, Gideon Bahn, Peter D. Reaven · 2016 · Diabetes Care
63. Understanding the impact of hypoglycemia on the cardiovascular system
    Ian Davis, Ida Ahmadizadeh, Jacqueline Randell, Lisa M. Younk, Stephen N. Davis · 2016 · Expert Review of Endocrinology & Metabolism
64. Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction
    M. Benalia, Marianne Zeller, Basile Mouhat, Charles Guénancia, Nobila Valentin Yaméogo, C. Greco, Hermann Yao, Maud Maza, Bruno L Vergès, Yves Cottin · 2019 · Diabetes & Metabolism
65. Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes
    Kamlesh Khunti, Samuel Seidu · 2019 · Diabetes Care
66. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
    Bruno L Vergès, Bernard H. Charbonnel · 2017 · Diabetes & Metabolism
67. Cardiovascular disease prevention strategies for type 2 diabetes mellitus
    Niki Katsiki, Francesco Purrello, Costas P. Tsioufis, Dimitri P. Mikhailidis · 2017 · Expert Opinion on Pharmacotherapy
68. Coronary artery disease and diabetes mellitus
    Mansour M. Al-Nozha, Hussein M Ismail, Omar Mansour Al Nozha · 2016 · Journal of Taibah University Medical Sciences
69. Longitudinal assessment of coronary plaque volume change related to glycemic status using serial coronary computed tomography angiography: A PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) substudy
    Ki‐Bum Won, Sang‐Eun Lee, Byoung Kwon Lee, Hyung‐Bok Park, Ran Heo, Asim Rizvi, Fay Yu-Huei Lin, Amit Kumar, Martin Hadamitzky, Yong-Jin Kim et al. · 2018 · Journal of cardiovascular computed tomography
70. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
    Anca Pantea Stoian, Alexandros G. Sachinidis, Roxana Adriana Stoica, Dragana Nikolić, Angelo Maria Patti, Ali Abbas Rizvi · 2020 · Metabolism
71. Does mean platelet volume/lymphocyte count ratio associate with frailty in type 2 diabetes mellitus?
    Satılmış Bilgin, Gülali Aktaş, Gizem Bakir Kahveci, B. M. Atak, Özge Kurtkulağı, Tuba Taslamacıoğlu Duman · 2021 · Bratislavské lekárske listy/Bratislava medical journal
72. Prevalence of Cardiovascular Disease and Associated Factors Among Type 2 Diabetes Patients in Selected Hospitals of Harari Region, Eastern Ethiopia
    Lemma Demissie Regassa, Assefa Tola, Yohanes Ayele · 2021 · Frontiers in Public Health
73. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: A population-based study
    Lega, Iliana C., Campitelli, Michael A., Austin, Peter C., Na, Yingbo, Zahedi, Afshan, Leung, Freda, Yu, Catherine, Bronskill, Susan E., Rochon, Paula A., Lipscombe, Lorraine L. · 2021 · Diabetologia
74. Epigenetics and Cardiovascular Disease in Diabetes
    Jennifer Pasquier, Jessica Hoarau-Véchot, Khalid Adnan Fakhro, Arash Rafii, Charbel Abi Khalil · 2015 · Current Diabetes Reports
75. ZLN005 protects cardiomyocytes against high glucose-induced cytotoxicity by promoting SIRT1 expression and autophagy
    Wenju Li, Xiaoli Li, Bin Wang, Yan Chen, Aiping Xiao, Di Zeng, Dong‐Bo Ou, Yan Song, Wei Li, Qiangsun Zheng · 2016 · Experimental Cell Research
76. Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia
    Clifford J. Bailey · 2016 · International Journal of Clinical Practice
77. Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
    Atsushi Tanaka, Koichi Node · 2016 · Journal of Cardiology
78. Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
    Matthew C. Riddle · 2017 · Diabetes Care
79. Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control
    Hina Trivedi, Laura J. Gray, Samuel Seidu, Melanie Jane Davies, Guillaume Charpentier, Ulf Lindblad, Christiane Kellner, John J. Nolan, Agnieszka Pazderska, Guy E.H.M. Rutten et al. · 2017 · Primary care diabetes
80. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
    Jingxin Li, Ke He, Jun Ge, Caixia Li, Zeng Jing · 2021 · Diabetes Research and Clinical Practice
81. Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet
    Mark T. Cucuzzella, Karen Riley, Diana M. Isaacs · 2021 · Frontiers in Nutrition
82. The effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world data
    Manuel Urina-Jassir, Lina Johana Herrera-Parra, Juliana Alexandra Hernández Vargas, Ana María Valbuena‐Garcia, Lizbeth Alexandra Acuña-Merchán, Miguel Urina‐Triana · 2021 · BMC Endocrine Disorders
83. The vascular complications of diabetes: a review of their management, pathogenesis, and prevention
    Juliet Meir, Lillian Huang, Sumaita Mahmood, Harris Z. Whiteson, Scott Cohen, Wilbert S. Aronow · 2023 · Expert Review of Endocrinology & Metabolism
84. Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes
    Juan Li, Xingping Shen · 2019 · Diabetology & Metabolic Syndrome
85. The importance of the initial period of basal insulin titration in people with diabetes
    Kamlesh Khunti, Francesco Giorgino, Lori Berard, Dı́dac Mauricio, Stewart B. Harris · 2019 · Diabetes Obesity and Metabolism
86. A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs
    Krishna Kumar Singh, Laura E. Mantella, Yi Pan, Adrian Quan, Sandra Sabongui, Paul Sandhu, Hwee Teoh, Mohammed A. Al-Omran, Subodh Verma · 2016 · Canadian Journal of Physiology and Pharmacology
87. Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals
    Zhijun Meng, Zhen Zhang, Jianli Zhao, Caihong Liu, Peng Yao, Ling Zhang, Dina Xie, Wayne Bond Lau, Jumpei Tsukuda, Theodore A. Christopher et al. · 2023 · Circulation
88. 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
    Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung‐Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo‐Kyung Kim, Young‐Eun Kim et al. · 2025 · Diabetes & Metabolism Journal
89. Fasting Glucose and All-Cause Mortality by Age in Diabetes: A Prospective Cohort Study
    Sang‐Wook Yi, Sangkyu Park, Yong‐ho Lee, Beverley Balkau, Jee‐Jeon Yi · 2018 · Diabetes Care
90. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus
    Miao Feng, Haihong Lv, Xia Xu, Jue Wang, Wenyi Lyu, Songbo Fu · 2019 · Medicine
91. miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
    Price, Nathan L, Goedeke, Leigh, Suárez, Yajaira, Fernández‐Hernando, Carlos · 2021 · EMBO Molecular Medicine
92. The metabolic memory phenomenon in predicting a risk for vascular complications in diabetes mellitus
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova · 2015 · Terapevticheskii arkhiv
93. Dysglycaemia as a cause of cardiovascular outcomes
    Hertzel C. Gerstein · 2015 · Nature Reviews Endocrinology
94. Effect of Long-Term Periodontal Care on Hemoglobin A1c in Type 2 Diabetes
    Anwar T. Merchant, Peter Georgantopoulos, Chanelle J. Howe, Salim S. Virani, Donald Morales, Kathlyn Sue Haddock · 2015 · Journal of Dental Research
95. Type 2 Diabetes Medication Review
    James Sterrett, Scott W. Bragg, Charles Wayne Weart · 2016 · The American Journal of the Medical Sciences
96. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
    Li Zang, Y. Liu, Jin Geng, Yuan Ming Luo, Fang Bian, X. Lv, Jian Yang, Jing Liu, Yan Peng, Yanrong Li et al. · 2016 · Diabetes Obesity and Metabolism
97. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis
    Shanshan Wu, Andrea Cipriani, Zhirong Yang, Jun Yang, Ting Cai, Yang Xu, Xiaochi Quan, Yuan Zhang, Sanbao Chai, Feng Sun et al. · 2018 · Expert Opinion on Drug Safety
98. Associations between sleep duration and sleep debt with insulin sensitivity and insulin secretion in the EGIR-RISC Study
    D. van Dijk, Beverley Balkau, Bérénice Segrestin, Mikael Gottsäter, Rafael Gabriel, Mensud Hatunic, Andrea Mari, J.M. Dekker, Femke Rutters · 2018 · Diabetes & Metabolism
99. L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes
    Stefano Menini, Carla Iacobini, Claudia Blasetti Fantauzzi, Giuseppe Pugliese · 2019 · Current Medicinal Chemistry
100. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
     Guntram Schernthaner, Marie Helene Schernthaner-Reiter, Gerit-Holger Schernthaner · 2016 · Clinical Therapeutics